danoprevir + ritonavir + RO5024048 + peginterferon alfa-2a + ribavirin

This regimen is an investigational combination of **two direct-acting antivirals** (danoprevir, a protease inhibitor; and RO5024048/mericitabine, a nucleoside polymerase inhibitor), boosted with the **pharmacokinetic enhancer ritonavir**, and combined with **peginterferon alfa-2a** (a pegylated type I interferon with antiviral and immunomodulatory effects), plus **ribavirin** (a nucleoside analog with broad-spectrum antiviral activity). The primary mechanistic intent is targeting different stages of the hepatitis C virus (HCV) life cycle, with the goal of higher sustained virological response and reduced resistance development compared to standard peginterferon plus ribavirin regimens. This investigational regimen has primarily been studied in **chronic hepatitis C** patients, including those with difficult-to-treat genotypes.

Brand names

PEGASYS (peginterferon alfa-2a)Norvir (ritonavir)no unique brand name for danoprevir + ritonavir + RO5024048 + peginterferon alfa-2a + ribavirin as a five-drug combination

Other names

mericitabine (RO5024048)combination is sometimes referred to as "triple or quadruple direct-acting antiviral therapy with interferon and ribavirin" in hepatitis C trial literature